CRISPR Therapeutics AG (CRSP) EBIT (2016 - 2025)
Historic EBIT for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$132.1 million.
- CRISPR Therapeutics AG's EBIT fell 1991.19% to -$132.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$574.4 million, marking a year-over-year decrease of 7280.55%. This contributed to the annual value of -$466.6 million for FY2024, which is 10965.68% down from last year.
- Per CRISPR Therapeutics AG's latest filing, its EBIT stood at -$132.1 million for Q3 2025, which was down 1991.19% from -$229.3 million recorded in Q2 2025.
- In the past 5 years, CRISPR Therapeutics AG's EBIT registered a high of $762.6 million during Q2 2021, and its lowest value of -$229.3 million during Q2 2025.
- Moreover, its 5-year median value for EBIT was -$132.1 million (2025), whereas its average is -$78.9 million.
- As far as peak fluctuations go, CRISPR Therapeutics AG's EBIT soared by 104513.25% in 2021, and later plummeted by 19282.15% in 2024.
- Quarter analysis of 5 years shows CRISPR Therapeutics AG's EBIT stood at -$145.7 million in 2021, then grew by 9.72% to -$131.5 million in 2022, then soared by 152.9% to $69.6 million in 2023, then tumbled by 192.82% to -$64.6 million in 2024, then crashed by 104.46% to -$132.1 million in 2025.
- Its EBIT stands at -$132.1 million for Q3 2025, versus -$229.3 million for Q2 2025 and -$148.4 million for Q1 2025.